Timeline of mutations and cytogenetic abnormalities
| Date . | Therapy . | Hb . | Blast % . | JAK2 p.V617F . | DNMT3A p.R882H . | IDH1 p.R132C . | RUNX1 p.D171N . | NRAS p.G12D . | NRAS p.Q61L . | ATM p.Q355H . | Cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | MEC induction | 7.5 | 27 | Neg | 35% | 30% | 46% | Neg | Neg | Neg | 49,XY,+Y,+8,+21[20]; FISH +8 and +21 (no % information, outside report) |
| 2 mo | Decitabine (2 cycles) | ||||||||||
| 5 mo | IDH1 inhibitor FT-2102 (13 cycles) | ||||||||||
| 15 mo | ND | 36 | Neg | 42.99% | 57.39% | 58.93% | Neg | Neg | Neg | 49,XY,+Y,+8,+21[19]/50,idem,+8[1]; FISH +8 and +21 (85.3%) | |
| 17 mo | 12.8 | 49 | 13.54% | 41.67% | 56.23% | 57.26% | Neg | Neg | Neg | 49,XY,+Y,+8,+21[19]/46,XY[1]; FISH: +8/+21 (84%) | |
| 18 mo | High-dose cytarabine reinduction | ||||||||||
| 19 mo | Azacitidine venetoclax (1 cycle) | 7.5 | 55 | 1.26% | 14.61% | 22.05% | 22.38% | Neg | Neg | Neg | FISH: +8 and +21 (42.3%) |
| 21 mo | Ivosidenib | 8.3 | 76 | 0.92% | 37.07% | 35.24% | 52.39% | Neg | Neg | Neg | FISH: +8 and +21 (47%) |
| 23 mo | 18.2 | 17 | 81.34% | 44.44% | 46.51% | 62.27% | Neg | Neg | 11.40% | 49,XY,+Y,+8,+21[20]; FISH: +8 and +21 (95.7%) | |
| 25 mo | 11.7 | 89 | 92.35% | 46.52% | 43.55% | 59.53% | Neg | 24.52% | 15.09% | 49,XY,+Y,+8,+21[19]/46,XY[1] | |
| 26 mo | Decitabine ruxolitinib (4 cycles) | ||||||||||
| 30 mo | Low-dose cytarabine venetoclax (1 cycle) | 12.6 | 80 | 92.22% | 43.68% | 45.52% | 64.24% | 4.39% | Neg | 43.57% | 49,XY,+Y,+8,+21[20]; FISH: +Y (73%) |
| Date . | Therapy . | Hb . | Blast % . | JAK2 p.V617F . | DNMT3A p.R882H . | IDH1 p.R132C . | RUNX1 p.D171N . | NRAS p.G12D . | NRAS p.Q61L . | ATM p.Q355H . | Cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | MEC induction | 7.5 | 27 | Neg | 35% | 30% | 46% | Neg | Neg | Neg | 49,XY,+Y,+8,+21[20]; FISH +8 and +21 (no % information, outside report) |
| 2 mo | Decitabine (2 cycles) | ||||||||||
| 5 mo | IDH1 inhibitor FT-2102 (13 cycles) | ||||||||||
| 15 mo | ND | 36 | Neg | 42.99% | 57.39% | 58.93% | Neg | Neg | Neg | 49,XY,+Y,+8,+21[19]/50,idem,+8[1]; FISH +8 and +21 (85.3%) | |
| 17 mo | 12.8 | 49 | 13.54% | 41.67% | 56.23% | 57.26% | Neg | Neg | Neg | 49,XY,+Y,+8,+21[19]/46,XY[1]; FISH: +8/+21 (84%) | |
| 18 mo | High-dose cytarabine reinduction | ||||||||||
| 19 mo | Azacitidine venetoclax (1 cycle) | 7.5 | 55 | 1.26% | 14.61% | 22.05% | 22.38% | Neg | Neg | Neg | FISH: +8 and +21 (42.3%) |
| 21 mo | Ivosidenib | 8.3 | 76 | 0.92% | 37.07% | 35.24% | 52.39% | Neg | Neg | Neg | FISH: +8 and +21 (47%) |
| 23 mo | 18.2 | 17 | 81.34% | 44.44% | 46.51% | 62.27% | Neg | Neg | 11.40% | 49,XY,+Y,+8,+21[20]; FISH: +8 and +21 (95.7%) | |
| 25 mo | 11.7 | 89 | 92.35% | 46.52% | 43.55% | 59.53% | Neg | 24.52% | 15.09% | 49,XY,+Y,+8,+21[19]/46,XY[1] | |
| 26 mo | Decitabine ruxolitinib (4 cycles) | ||||||||||
| 30 mo | Low-dose cytarabine venetoclax (1 cycle) | 12.6 | 80 | 92.22% | 43.68% | 45.52% | 64.24% | 4.39% | Neg | 43.57% | 49,XY,+Y,+8,+21[20]; FISH: +Y (73%) |
Hb, hemoglobin; MEC, mitoxantrone, etoposide, and cytarabine; ND, no data; neg, negative.